Navigation Links
Dyadic International Reports 2010 Third Quarter Financial Results
Date:11/15/2010

JUPITER, Fla., Nov. 15, 2010 /PRNewswire-FirstCall/ -- Dyadic International, Inc. ("Dyadic") (Pink Sheets: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced financial results for the third quarter ended September 30, 2010. The financial information contained in this press release should be read in conjunction with the financial statements and related footnotes which have been posted on the Pink Sheets website at www.pinksheets.com and on Dyadic's website at www.dyadic.com.

(Logo: http://photos.prnewswire.com/prnh/20091214/DYADICLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20091214/DYADICLOGO)

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "During the third quarter, we improved our cash position, increased our enzyme sales and made progress in further developing our internal and external efforts to identify, negotiate and secure new licensing opportunities and other strategic collaborations for our core technologies."

Recent Company HighlightsIn the third quarter of 2010, Dyadic made progress in the following areas:

Cash Position

  • Improved cash position by raising an aggregate of $4,000,000 through the private placement of convertible subordinated secured promissory notes

  • Industrial Enzymes

  • Increased sales by 15% in the third quarter as compared to the same period a year ago
  • Improved product mix resulting in increased product margins of 31% for the year to date as compared to 22% for the same period a year ago
  • Expanded distribution network to increase product availability in remote markets
  • Introduced ROCKS
    '/>"/>

  • SOURCE Dyadic International, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Dyadic International to Announce Third Quarter 2010 Financial Results and Hold Conference Call on November 15, 2010
    2. Dyadic International Raises $3 Million in Private Placement of Convertible Notes
    3. Dyadic International to Announce Second Quarter 2010 Financial Results and Hold Conference Call on August 13, 2010
    4. Dyadic International Announces Final Resolution and Dismissal of Stockholder Class Action Lawsuit
    5. Dyadic International Engages The Abraham Group as Strategic Advisor
    6. Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
    7. Dyadic International Strengthens Management Team
    8. Dyadic International Extends Collaboration With The Scripps Research Institute
    9. International Technidyne Corporation Acquired by Warburg Pincus
    10. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
    11. Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... PharmaBoardroom,s new report, , Healthcare and ... free download , digs deep into this vibrant market, ... sector today. One area where Algeria ... a homegrown pharmaceutical manufacturing base, even if the government,s ambitious ... off. A cursory comparison with neighboring Morocco ...
    (Date:12/24/2014)... YORK , Dec. 23, 2014  NeuroLifeSciences announced ... mazindol in children with attention deficit/hyperactivity disorder published in ... . The paper, titled "Pilot Phase ... disorder" ( Konofal et al, Drug Des ... ) shows that mazindol might be an effective, ...
    (Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, ... the University of Calgary in conjunction with co-authors from ... further validates the company,s ongoing clinical research using dermal ... pattern baldness. The paper entitled " Hair ...
    (Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
    Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
    ... , ROCKVILLE, Md., Nov. 30 Novavax, Inc. (Nasdaq: NVAX ... be presenting at the 21st Annual Health Care Conference 2009 on ... York Palace, New York. Novavax will provide an overview of ... A link to the live audio only presentation can be ...
    ... , CHANGCHUN, China ... Inc. (OTC Bulletin Board: CYXN; ,China Yongxin,Pharmaceuticals, or ,the ... Northeastern China, today announced it has,completed preparation for distribution ... The Chinese government recently formalized the ...
    ... ... (Nasdaq and MTA: CTIC) announced today that its new ... stronger anti-tumor potency and activity compared to currently available ... cisplatin-resistance in cancer cell lines. The results were ...
    Cached Biology Technology:NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3
    (Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
    (Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
    (Date:12/10/2014)... -- CIE San Diego has launched an innovative trust ... that enhances care coordination among social service and care ... earned a second $1 million grant from the Alliance ... in community and; will be recognized as a "Live ... 4-6p. CIE San Diego today announced the ...
    Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
    ... release is available in German . Plants, ... The early detection of pathogens and the subsequent immune response, ... shield. However, the pathogens that cause plant diseases have their ... wall reaction in plants. "One particularly ingenious attacker, powdery mildew, ...
    ... The scientific equivalent of searching for a needle in ... for potential new medicines for Parkinson,s Disease and other ... American Chemical Society,s award-winning " Global Challenges/Chemistry Solutions " ... 390,000 chemical compounds. Finally, they located one that blocks ...
    ... children to stop slouching for ages. It turns out ... only makes a bad impression, but can actually make you ... professor of management organization at the USC Marshall School of ... Rotman School of Management at the University of Toronto, adopting ...
    Cached Biology News:TUM researchers discover a new switch in resistance to plant diseases 2Your mother was right: Study shows good posture makes you tougher 2
    ... • Enzyme concentration - 5 units/µL ,• ... higher yields ,• Leaves an 'A' overhang ... polymerase which exhibits very high activity in ... To ensure the quality of the enzyme, ...
    ... 5 units/µL ,• High specific activity and ... an 'A' overhang ,• Processes ... very high activity in primer extension and ... quality of the enzyme, each lot has ...
    Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
    A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
    Biology Products: